AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9220221 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 299
Study 8421977 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of epsilon 4 allele
Number of subjects: 619
Study 8421977 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of epsilon 2 allele
Number of subjects: 619
Study 8421977 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in LDL cholesterol over time
Number of subjects: 619
Study 3798631 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide (250 mg X 3)
Number of subjects: 30
Study 3798631 — intervention group
Group type: COMPARATOR
Intervention: Estramustine (280 mg X 2)
Number of subjects: 30
Study 31162372 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous breathing trial (CPAP with 10 cmH2O pressure support, 5 cmH2O PEEP, FiO2 ≤ 0.5 for 2 hours)
Number of subjects: 110
Study 31162372 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous breathing trial
Number of subjects: 110
Study 31162372 — intervention group
Group type: COMPARATOR
Intervention: Control group (ventilator weaning according to clinical judgment)
Number of subjects: 110
Study 28855115 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter Ablation (CA)
Number of subjects: 68
Study 28855115 — intervention group
Group type: COMPARATOR
Intervention: Medical Rate Control (MRC)
Number of subjects: 68
Study 26017126 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic hypothermia at 33°C initiated within 3 hours of injury and continued for at least 72 hours
Number of subjects: 500
Study 26017126 — intervention group
Group type: COMPARATOR
Intervention: Standard normothermic management
Number of subjects: 500
Study 26017126 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic hypothermia
Number of subjects: 500
Study 23747076 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Number of subjects: 0
Study 23747076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21357280 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized diet to gain ≈4 kg over 8 weeks
Number of subjects: 36
Study 21357280 — intervention group
Group type: COMPARATOR
Intervention: Weight-maintainer control
Number of subjects: 36
Study 19522391 — intervention group
Group type: EXPERIMENTAL
Intervention: Liqi decoction (oral for 2 to 3 days)
Number of subjects: 75
Study 19522391 — intervention group
Group type: COMPARATOR
Intervention: Control group (fasting and enema, gastrointestinal decompression)
Number of subjects: 75
Study 16769828 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk prethreshold ROP
Number of subjects: 0
Study 16769828 — intervention group
Group type: COMPARATOR
Intervention: Low-risk prethreshold ROP
Number of subjects: 0
Study 15615325 — intervention group
Group type: EXPERIMENTAL
Intervention: Just breakfast
Number of subjects: 10
Study 15615325 — intervention group
Group type: EXPERIMENTAL
Intervention: Just lunch
Number of subjects: 10
Study 15615325 — intervention group
Group type: EXPERIMENTAL
Intervention: Both lunch and breakfast
Number of subjects: 10
Study 15615325 — intervention group
Group type: EXPERIMENTAL
Intervention: No meal at all
Number of subjects: 10
Study 11398073 — intervention group
Group type: EXPERIMENTAL
Intervention: Grass pollen immunotherapy
Number of subjects: 37
Study 11398073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 9244032 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 8 mg
Number of subjects: 124
Study 9244032 — intervention group
Group type: COMPARATOR
Intervention: metoclopramide 10 mg
Number of subjects: 124
Study 9244032 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 124
Study 8490411 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' recall of information immediately after signing the consent form
Number of subjects: 265
Study 8490411 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 265
Study 8490411 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive function
Number of subjects: 265
Study 8490411 — intervention group
Group type: EXPERIMENTAL
Intervention: IQ
Number of subjects: 265
Study 8490411 — intervention group
Group type: EXPERIMENTAL
Intervention: Health locus of control
Number of subjects: 265
Study 8490411 — intervention group
Group type: EXPERIMENTAL
Intervention: Operation information cards
Number of subjects: 265
Study 8490411 — intervention group
Group type: EXPERIMENTAL
Intervention: Written information
Number of subjects: 265
Study 8490411 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients not reading the consent form before signing
Number of subjects: 265
Study 2824707 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide (1,200 mg/m2), doxorubicin (70 mg/m2), and vincristine (1 mg/m2) (HDCAV)
Number of subjects: 298
Study 2824707 — intervention group
Group type: COMPARATOR
Intervention: Conventional-dose cyclophosphamide (1,000 mg/m2), doxorubicin (40 mg/m2), and vincristine (1 mg/m2) (CDCAV)
Number of subjects: 298
Study 29615792 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic and resistance training for 16 weeks
Number of subjects: 150
Study 29615792 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 150
Study 26150093 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-facilitated 5As (CF-5As) intervention
Number of subjects: 0
Study 26150093 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CF-5As intervention)
Number of subjects: 0
Study 25130289 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefozopran (CZOP) 100mg/kg/day
Number of subjects: 64
Study 25130289 — intervention group
Group type: COMPARATOR
Intervention: Cefepime (CFPM) 100mg/kg/day
Number of subjects: 64
Study 25130289 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 64
Study 22672334 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultured allogeneic keratinocyte sheets
Number of subjects: 59
Study 22672334 — intervention group
Group type: COMPARATOR
Intervention: Vaseline gauze (Control)
Number of subjects: 59
Study 20347922 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser (80mJ/2Hz) at 4mm with cooling
Number of subjects: 84
Study 20347922 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser (80mJ/2Hz) at 4mm without cooling
Number of subjects: 84
Study 20347922 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser (80mJ/2Hz) at 8mm with cooling
Number of subjects: 84
Study 20347922 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser (80mJ/2Hz) at 8mm without cooling
Number of subjects: 84
Study 20347922 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser (80mJ/2Hz) at 16mm with cooling
Number of subjects: 84
Study 20347922 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser (80mJ/2Hz) at 16mm without cooling
Number of subjects: 84
Study 20347922 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 84
Study 18555063 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety sensitivity (AS)
Number of subjects: 0
Study 18555063 — intervention group
Group type: COMPARATOR
Intervention: Control for sex and negative affectivity
Number of subjects: 0
Study 16209961 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine group
Number of subjects: 166
Study 16209961 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 166
Study 16209961 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (ECG and SPECT techniques)
Number of subjects: 166
Study 11785996 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated heart failure management programme
Number of subjects: 197
Study 11785996 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 197
Study 10522954 — intervention group
Group type: EXPERIMENTAL
Intervention: EX1 (1 day per week)
Number of subjects: 46
Study 10522954 — intervention group
Group type: EXPERIMENTAL
Intervention: EX2 (2 days per week)
Number of subjects: 46
Study 10522954 — intervention group
Group type: EXPERIMENTAL
Intervention: EX3 (3 days per week)
Number of subjects: 46
Study 10522954 — intervention group
Group type: COMPARATOR
Intervention: CO (Control group)
Number of subjects: 46
Study 10522954 — intervention group
Group type: EXPERIMENTAL
Intervention: All exercise groups (EX1, EX2, EX3)
Number of subjects: 46
Study 10155051 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized albuterol and cromolyn sulfate
Number of subjects: 246
Study 10155051 — intervention group
Group type: EXPERIMENTAL
Intervention: Home aerosol treatments after intramuscular injection of dexamethasone
Number of subjects: 246
Study 1362189 — intervention group
Group type: EXPERIMENTAL
Intervention: Norgestimate-containing OC
Number of subjects: 2197
Study 6369456 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpropamide (single dose)
Number of subjects: 0
Study 6369456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31259617 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergame intervention (EG) for 24 weeks, 120 minutes per week, divided into two sessions of 60 minutes each.
Number of subjects: 55
Study 31259617 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergame intervention (EG)
Number of subjects: 55
Study 31259617 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 55
Study 29456937 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous incus (Group A)
Number of subjects: 88
Study 29456937 — intervention group
Group type: COMPARATOR
Intervention: Titanium prosthesis (Group B)
Number of subjects: 88
Study 24549033 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year school-based intervention program
Number of subjects: 465
Study 24549033 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 465
Study 22075273 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut-enriched diet (48 g/d for 4 days)
Number of subjects: 15
Study 22075273 — intervention group
Group type: COMPARATOR
Intervention: Placebo diet
Number of subjects: 15
Study 19412190 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nitroglycerin formulation
Number of subjects: 0
Study 19412190 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment options
Number of subjects: 0
Study 17244294 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash and Counseling (treatment group)
Number of subjects: 0
Study 17244294 — intervention group
Group type: COMPARATOR
Intervention: Medicaid services as usual (control group)
Number of subjects: 0
Study 15197669 — intervention group
Group type: COMPARATOR
Intervention: Double lumen tube (DLT)
Number of subjects: 32
Study 15197669 — intervention group
Group type: EXPERIMENTAL
Intervention: Arndt bronchial blocker (BB)
Number of subjects: 32
Study 11967497 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous combined hormone replacement therapy (E(2)/NETA)
Number of subjects: 166
Study 11967497 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg
Number of subjects: 166
Study 11967497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study 11967497 — intervention group
Group type: COMPARATOR
Intervention: E(2)/NETA vs Placebo
Number of subjects: 166
Study 11967497 — intervention group
Group type: EXPERIMENTAL
Intervention: E(2)/NETA vs Tibolone
Number of subjects: 166
Study 11967497 — intervention group
Group type: COMPARATOR
Intervention: Tibolone vs Placebo
Number of subjects: 166
Study 9717036 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg sublingual 17 beta-oestradiol
Number of subjects: 12
Study 9717036 — intervention group
Group type: COMPARATOR
Intervention: 2.5 mg buccal nitroglycerine
Number of subjects: 12
Study 9717036 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7816519 — intervention group
Group type: COMPARATOR
Intervention: Healthy children (control group), n = 7
Number of subjects: 7
Study 7816519 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with Zellweger syndrome (ZS)
Number of subjects: 7
Study 3400639 — intervention group
Group type: EXPERIMENTAL
Intervention: AST-120 (3.2 to 7.2 g/d) administered for 2.4 to 30.1 months (mean 13.2 +/- 7.4 months)
Number of subjects: 51
Study 3400639 — intervention group
Group type: COMPARATOR
Intervention: Control group (no AST-120)
Number of subjects: 51
Study 3400639 — intervention group
Group type: EXPERIMENTAL
Intervention: AST-120 (3.2 to 7.2 g/d)
Number of subjects: 51
Study 29419341 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported tobacco use
Number of subjects: 207
Study 29419341 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported marijuana use
Number of subjects: 207
Study 29419341 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported use of other substances (heroin, cocaine, opiates, oxycodone, benzodiazepines, methamphetamine, phencyclidine, barbiturates)
Number of subjects: 207
Study 28490394 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation
Number of subjects: 54
Study 28490394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 26038252 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol management intervention
Number of subjects: 88
Study 26038252 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 88
Study 23775967 — intervention group
Group type: EXPERIMENTAL
Intervention: ETV prophylactic group (n = 41)
Number of subjects: 80
Study 23775967 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 39)
Number of subjects: 80
Study 20202271 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial, interdisciplinary team approach to falls prevention
Number of subjects: 109
Study 18226671 — intervention group
Group type: EXPERIMENTAL
Intervention: 91-day extended-regimen oral contraceptive (OC) with low-dose ethinyl estradiol (EE)
Number of subjects: 63
Study 18226671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 16607146 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (omeprazole, clarithromycin, amoxicillin for 10 days)
Number of subjects: 122
Study 16607146 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple therapy (omeprazole, amoxicillin, metronidazole, bismuth citrate for 10 days)
Number of subjects: 122
Study 16607146 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful eradication therapy
Number of subjects: 122
Study 12565981 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide local excision (WLE) and tamoxifen (T) 20 mg daily
Number of subjects: 236
Study 12565981 — intervention group
Group type: COMPARATOR
Intervention: Modified radical mastectomy (MRM)
Number of subjects: 236
Study 11004045 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalaprilat 1.25 mg IV followed by multidose nicardipine 2 mg IV
Number of subjects: 42
Study 11004045 — intervention group
Group type: COMPARATOR
Intervention: Enalaprilat 1.25 mg IV followed by labetalol 5 mg IV
Number of subjects: 42
Study 8864334 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for asymptomatic ischemia using stress tests and ambulatory ECG
Number of subjects: 1820
Study 8864334 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomization for revascularization
Number of subjects: 1820
Study 8864334 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiographic evidence of coronary artery disease
Number of subjects: 1820
Study 1562862 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional ECT with constant-voltage modified sine-wave stimuli (n = 17)
Number of subjects: 31
Study 1562862 — intervention group
Group type: EXPERIMENTAL
Intervention: Modern, constant-current brief-pulse ECT (n = 14)
Number of subjects: 31
Study 3863913 — intervention group
Group type: EXPERIMENTAL
Intervention: Flap design group 1
Number of subjects: 30
Study 3863913 — intervention group
Group type: EXPERIMENTAL
Intervention: Flap design group 2
Number of subjects: 30
Study 3863913 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial height of alveolar bone
Number of subjects: 30
Study 31888742 — intervention group
Group type: EXPERIMENTAL
Intervention: FKB327 40 mg via prefilled syringe (PFS)
Number of subjects: 195
Study 31888742 — intervention group
Group type: EXPERIMENTAL
Intervention: FKB327 40 mg via auto-injector (AI)
Number of subjects: 195
Study 31888742 — intervention group
Group type: COMPARATOR
Intervention: FKB327 40 mg via vial with disposable syringe
Number of subjects: 195
Study 29198070 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 14
Study 26908949 — intervention group
Group type: EXPERIMENTAL
Intervention: PFO closure using Amplatzer PFO Occluder
Number of subjects: 107
Study 26908949 — intervention group
Group type: COMPARATOR
Intervention: Medical management (control)
Number of subjects: 107
Study 24158488 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbicide gel adherence in women with ongoing partners
Number of subjects: 1757
Study 24158488 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbicide gel adherence in women with new partners
Number of subjects: 1757
Study 24158488 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom use in women with new partners
Number of subjects: 1757
Study 24158488 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom use in women with ongoing partners
Number of subjects: 1757
Study 24158488 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of both gel and condom in women with new partners
Number of subjects: 1757
Study 24158488 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of both gel and condom in women with ongoing partners
Number of subjects: 1757
Study 24158488 — intervention group
Group type: EXPERIMENTAL
Intervention: High gel adherence in women with ongoing partners
Number of subjects: 1757
Study 24158488 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV incidence in women with new partners
Number of subjects: 1757
Study 24158488 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV incidence in women with ongoing partners
Number of subjects: 1757
Study 22701339 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion at a target organ concentration of 2.0 ng/mL
Number of subjects: 30
Study 22701339 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 30
Study 20419581 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-focused cognitive behavior therapy (CBT) plus parental anxiety management (PAM)
Number of subjects: 60
Study 20419581 — intervention group
Group type: COMPARATOR
Intervention: Child-focused cognitive behavior therapy (CBT)
Number of subjects: 60
Study 18948245 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS therapy
Number of subjects: 60
Study 18948245 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 60
Study 18948245 — intervention group
Group type: COMPARATOR
Intervention: Control (pharmacologic analgesia alone)
Number of subjects: 60
Study 16161735 — intervention group
Group type: COMPARATOR
Intervention: 100% autogenous bone (control side)
Number of subjects: 18
Study 16161735 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:1 mixture of autogenous bone and corticocancellous pig bone particles (test side)
Number of subjects: 18
Study 12380788 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 52
Study 12380788 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 52
Study 10428130 — intervention group
Group type: EXPERIMENTAL
Intervention: Early restricted motion of the ankle in a below-the-knee brace for six weeks
Number of subjects: 71
Study 10428130 — intervention group
Group type: COMPARATOR
Intervention: Conventional postoperative management with a cast for eight weeks
Number of subjects: 71
Study 7755384 — intervention group
Group type: EXPERIMENTAL
Intervention: AO-90 (500-750 mL/day)
Number of subjects: 53
Study 7755384 — intervention group
Group type: COMPARATOR
Intervention: C/MF group (Amiparen, 600-800 mL/day)
Number of subjects: 53
Study 7755384 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (AO-90 and C/MF)
Number of subjects: 53
Study 2304739 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (1000 mg three times a day)
Number of subjects: 59
Study 2304739 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucamethacin (140 mg three times a day)
Number of subjects: 59
Study 2304739 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and Glucamethacin
Number of subjects: 59
Study 2304739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 2304739 — intervention group
Group type: COMPARATOR
Intervention: Aspirin, Glucamethacin, and Placebo
Number of subjects: 59
Study 440850 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care program participants
Number of subjects: 0
Study 440850 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 31376194 — intervention group
Group type: EXPERIMENTAL
Intervention: P2post group (n = 408 players)
Number of subjects: 806
Study 31376194 — intervention group
Group type: COMPARATOR
Intervention: Standard-11+ group (n = 398 players)
Number of subjects: 806
Study 27996349 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted surgery (CAS)
Number of subjects: 54
Study 27996349 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery (CONV)
Number of subjects: 54
Study 24991946 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer
Number of subjects: 200
Study 24991946 — intervention group
Group type: EXPERIMENTAL
Intervention: P-selectin
Number of subjects: 200
Study 24991946 — intervention group
Group type: EXPERIMENTAL
Intervention: Microparticles
Number of subjects: 200
Study 24991946 — intervention group
Group type: COMPARATOR
Intervention: D-dimer, P-selectin, and microparticles
Number of subjects: 200
Study 23615154 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement Music Therapy (MMT)
Number of subjects: 112
Study 23615154 — intervention group
Group type: COMPARATOR
Intervention: Control group (simple exercise program)
Number of subjects: 112
Study 20407860 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Navigation (PN) programs
Number of subjects: 21
Study 19075278 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate docetaxel (75 mg/m² on day 1 every 21 days, maximum of six cycles)
Number of subjects: 566
Study 19075278 — intervention group
Group type: COMPARATOR
Intervention: Delayed docetaxel
Number of subjects: 566
Study 19075278 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate docetaxel
Number of subjects: 566